Molecular Imaging enters agreement with Dana-Farber to expand cancer cell lines

Multi-modality preclinical in-vivo imaging services provider Molecular Imaging (Ann Arbor, MI) has entered into a licensing agreement with Dana-Farber Cancer Institute (Boston, MA), which grants Molecular Imaging access to a substantial number of luciferase-enabled cancer cell lines developed at Dana-Farber. Now, Molecular Imaging has expanded ability to apply bioluminescent imaging technology to a broad array of cancer disease models, including expanded capability in various leukemias, multiple myeloma, triple-negative breast cancer, glioma, and melanoma.

Molecular Imaging will be collaborating with Andrew Kung, MD, Ph.D., and Scott Armstrong, MD, Ph.D., both of Dana-Farber, to further develop and make available these, and other cell lines, to improve the quantification and predictive power of bioluminescent imaging in cancer. The agreement gives Molecular Imaging access to over 100 additional luciferase-enabled cell lines, providing the ability to use imaging in a much broader array of cancer disease models, with greater confidence, says W. R. Leopold, Ph.D., VP of research and development at Molecular Imaging.

Kung is director of the Lurie Family Imaging Center at Dana-Farber and associate professor of pediatrics at Dana-Farber, Children's Hospital Boston and Harvard Medical School. Armstrong is also an associate professor of pediatrics at Dana-Farber, Children's Hospital Boston and Harvard Medical School and is co-director of both the Cancer Program/Harvard Stem Cell Institute and Dana-Farber/Harvard Cancer Center's Leukemia program.

-----

Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn

Follow OptoIQ on your iPhone; download the free app here.

Subscribe now to BioOptics World magazine; it's free!